Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium
Part of paid clinical trials in Los Angeles, California.
- Sponsor
- National Cancer Institute (NCI)
- Study ID
- NCT00363883
- Phase
- PHASE2
- Status
- Terminated
Conditions
- Localized Transitional Cell Cancer of the Renal Pelvis and Ureter
- Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
- Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
- Regional Transitional Cell Cancer of the Renal Pelvis and Ureter
- Transitional Cell Carcinoma of the Bladder
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- vorinostat — DRUGGiven orally
- laboratory biomarker analysis — OTHERCorrelative studies
Study Details
Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well vorinostat works in treating patients with locally recurrent or metastatic cancer of the urothelium.
Key Dates
- Start date
- Jun 30, 2006
- Status verified
- Jan 2014
- Primary completion
- Dec 31, 2010
- Completion
- Dec 31, 2010
Study Design
- Enrollment
- 14 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment (vorinostat)Patients receive oral vorinostat (SAHA) twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Primary Outcome Measure
Objective Tumor Response Rate [ Time Frame: Response assessed after every 2 cycles (6 weeks) up to 26 weeks ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Southern California, Norris | Los Angeles | California | 90033 | - |
Find similar trials in Los Angeles, CA
By research site